




1/23




2/23

**Fig. 1B**


3/23




4/23

**Fig. 2B**


5/23




6/23




7/23




8/23



9/23



10/23

**Fig. 5B**

11/23






Fig. 6A


12/23

**Fig. 6B**


13/23




14/23




15/23




16/23




17/23




18/23



19/23




20/23




21/23

Fig. 9C



22/23

10
Figure 3a. Determination of ApoC-III level in 14 haemorrhagic and 13 ischaemic stroke plasma samples compared to 30 negative controls using Daiichi tests (Cobas Mira plus automate)



	p (student test)	Sensitivity	Specificity
I vs H	0.0342	92.3 %	71.42 %
I vs Ctrl	0.025	92.3 %	50 %
H vs Ctrl	0.4682	-	-

23/23

Fig. 11

